Rationale: N-butyldeoxynojyrimicin (NB-DNJ, miglustat [Zavesca]) an approved drug for treating Gaucher disease, was reported to be able to correct the defective trafficking of the F508del-CFTR protein.
Cystic fibrosis (CF) is caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene resulting in malfunctioning or reduction of the CFTR protein through a variety of mechanisms (1, 2) . The protein has an essential role in transepithelial ion transport, functioning as an ohmic, small conductance, cAMP-dependent chloride channel but also regulating many other transport proteins, most notably the epithelial sodium channel (ENaC) (3, 4) . The most prevalent CF-causing mutation, F508del, is a misfolded protein that fails to escape the endoplasmic reticulum (ER) and reach the apical membrane of many epithelial cell types (5) (6) (7) .
The loss of CFTR function can be assessed in vivo by measuring the transepithelial nasal potential difference (PD), which has been increasingly used as an index of therapeutic efficacy in novel fundamental therapies either in patients (8, 9) or in animal models (10) .
Despite the clear link between abnormal ion transport and CF, the pathogenesis of lung disease in CF is complex and still debated. The initiating event in CF-airway disease pathogenesis seems to be reduced airway surface liquid volume that develops, in large part, as a consequence of abnormal ion transport. A compound capable of rescuing the F508del protein function and of normalizing ion transport abnormalities could be considered, in contrast to symptomatic or alleviating treatments currently available, as a disease-modifying therapeutic agent and would be beneficial for most patients with CF.
The generation of animal models that mimic the human phenotype has been an important achievement in CF research. To date, 13 mouse models have been created and 3 F508del strains are available (11) . The prevalence of the F508del mutation along with its severe phenotype makes the F508del-CF mouse a useful model to test novel pharmaceutics that target the mutant CFTR processing and turnover (10) .
Miglustat, an N-alkylated iminosugar (n-butyldeoxynojyrimicin, [NB-DNJ], Zavesca) is an orally available drug approved for use in patients with nonneuronopathic, type I Gaucher disease, an inherited glycosphingolipid lysosomal storage disorder (12) (13) (14) . The drug has also been considered in the treatment of other glycosphingolipidoses (15) as well as viral infections (16, 17) . Its efficacy has been investigated in CF experimental models such as F508del mutant airway epithelial cells in culture or isolated tissues from mice (18) (19) (20) (21) (22) . Oral treatment with miglustat in patients with CF is now being evaluated within a pilot phase 2a clinical trial at our CF center (http://clinicaltrials.gov/ct2/show/ NCT00742092). Miglustat is an inhibitor of several enzymes, including the ceramide-specific glucosyltransferase, disaccharidases, and a-glucosidases. Inhibition of the former enzyme, which initiates the glycosphingolipid biosynthetic pathway and catalyzes the formation of glucocerebroside, provides the rationale for the use of miglustat in glycophospholipid storage diseases (12) (13) (14) (15) . Inhibition of intestinal disaccharidases, such as sucrase, maltase, and lactase, has been related to the high incidence of diarrhea, flatulence, and abdominal pain in patients orally treated with miglustat. Inhibition of a-glucosidase has been suggested as the underlying mechanism of the CFTR corrector effect of miglustat in CF tissues (18) (19) (20) . The corrective effect of miglustat AT A GLANCE COMMENTARY Scientific Knowledge on the Subject Miglustat, an approved oral therapy for Gaucher disease, has been shown to partially correct defective trafficking of F508del-CFTR.
What This Study Adds to the Field
Nasal deposition of miglustat improves both chloride and sodium transport in F508del-CFTR mice, warranting further studies of topical miglustat as potential therapy for cystic fibrosis.
has been identified in CF cell cultures grown on impermeable plastic dishes, a configuration that allows interaction of drugs through the apical side of epithelia (18) (19) (20) (21) (22) . Therefore, we hypothesized that in vivo topical application of miglustat to the airway epithelium is able to restore transepithelial ion transport abnormalities of the F508del-CFTR protein. In the present work, we investigated in CF mice homozygous for the F508del mutation (23), in cftr knockout mice, and in their corresponding wild-type homozygous normal mice, the effect of in vivo treatment by nasal instillation of miglustat on parameters of the transepithelial potential difference (PD) across the nasal mucosa. Our results provide clear evidence that local delivery of miglustat, at picomolar doses, to the airway epithelium counteracts sodium transport even in the absence of CFTR, and activates CFTR-dependent chloride transport in F508del-CF mice. These data highlight the potential of topical miglustat as a therapy for CF.
METHODS

Animal Model
The study investigated CF mice homozygous for the F508del-CFTR mutation in the 129/FVB outbred background (cftr tm1Eur ) (23) and their wild-type normal homozygous littermates, which were housed at the Animal Care Facility of our University following recommendations of the Federation of European Laboratory Animal Science Associations (24) . Mice were 3 to 4 months of age and weighed between 20 and 30 grams. To prevent CF intestinal obstruction, Movicol (55.24 g/L; Norgine, Heverlee, Belgium) was administered in acidified drinking water. The mice were genotyped at 21 days of age by using Taqman quantitative polymerase chain reaction (PCR), as previously described (25) . C57Bl/6 cftr UNC knockout mice and their wild-type controls were also investigated. All experiments were approved by the local Ethics Committee for Animal Welfare and conformed to the European Community regulations for animal use in research (CEE N8 86/609).
Pharmacological Agents
Miglustat was applied by nasal instillation of 5 ml solution by using a pipette (26) . N-butyldeoxygalactonojirimycin (NB-DGJ), a galactose iminosugar analog without a-glucosidase-inhibitory activity (27) , was used as a placebo at 100 mM concentration. In dose-response experiments, a nasal PD test was performed after nasal deposition, in each nostril, of saline or miglustat solution applied at different concentrations varying from 0.1 mM to 100 mM. Topical nasal application of iminosugars was performed under light sedation induced over 5 minutes after intraperitoneal injection of 0.25 mg midazolam (Dormicum; Roche, Brussels, Belgium). To allow uniform dispersal of intranasal deposited drug, both nostrils were subsequently instillated with the same volume of solution and the animal was kept for 2 to 3 minutes in an upright position to prevent an unknown amount of drug being coughed up or swallowed. The effect on nasal PD parameters was examined 1 hour or 6 hours after miglustat administration. Iminosugar drugs were purchased from Toronto Research Chemicals (Toronto, ON, Canada). All other chemicals were from Sigma Aldrich (St. Louis, MO). Solutions with iminosugars were prepared in saline, stored at 48 C, and used within 4 days after preparation.
Nasal Potential Difference Measurements
Nasal PD measurements were performed under general anesthesia as previously described (10, 28) . In brief, a double lumen catheter was placed in a nasal passage, and a needle inserted in the subcutaneous space in a hind leg served as a reference bridge. Solutions were perfused at a constant rate of 12 ml/min. The following parameters were recorded: (1) the most negative stable baseline PD value (PDmax); (2) 
Statistics
Descriptive statistics (mean and SEM) and tests of significance were performed using SAS-JMP software (SAS Institute, Cary, NC). Betweengroup comparisons were evaluated using one-way analysis of variance. Posthoc comparisons were made using Student's t test or Tukey-Kramer test for two or more x levels, respectively. Null hypothesis was rejected at P , 0.05. 
RESULTS
As
Nasal Deposition of Miglustat Reduces Sodium Transport in F508del Mice
Nasal deposition of miglustat and NB-DGJ was well tolerated and no adverse effect was observed. A nasal PD test was undertaken in F508del and wild-type mice 1 hour after nasal instillation with miglustat or placebo. The concentration of 100 mM was initially selected because correction of ion transport was reported in epithelial cells in culture 2 hours after incubation in the presence of this concentration in the culture medium (18) . Placebo experiments were performed 1 hour after nasal instillation of 5 ml of 100 mM of the galactose iminosugar analog, NB-DGJ (27) .
As illustrated in Figures 1A-1B , the tracing profile obtained in F508del mice 1 hour after nasal instillation of miglustat was similar to that observed in placebo-treated wild-type mice. A significant reducing effect on PDmax was detected in F508del mice while comparing miglustat-treated to placebo-treated animals ( Figure 2A ). PDmax in F508del mice after miglustat reached identical values to those recorded in placebo wild-type mice ( Figure 2A ). The normalizing effect of miglustat on sodium conductance in F508del animals was confirmed on the amiloride sensitivity. Indeed, mean (6 SEM) values of amiloride response were higher in placebo-treated (22.1 6 1.2 mV; n 5 7) than in miglustat-treated F508del mice (15.8 6 1.5 mV; n 5 5; P 5 0.005). No significant effect of miglustat was detected in the normal homozygous control group, neither on basal PD values ( Figure  2A ) nor on amiloride response (data not shown).
Nasal Deposition of Miglustat Increases Chloride Transport in F508del Mice
A significant effect on chloride transport was detected in F508del mice 1 hour after nasal deposition of 5 ml in each nostril of 100 mM miglustat ( Figure 1A-1B) . Indeed, chloride conductance was twofold higher in F508del mice treated with miglustat compared with the corresponding placebo-treated group ( Figure 2B) . Moreover, SumCl values in F508del mice after miglustat treatment were comparable to those values recorded in placebotreated wild-type group ( Figure 2B ). No significant effect was observed in the wild-type group when comparing miglustattreated to placebo-treated animals ( Figure 2B ).
Influence of Alternative Chloride Transport Pathways on the Effect of Miglustat
To determine whether the effect of nasal instillation of miglustat in increasing chloride transport across the nasal epithelium of F508del mice is dependent on alternative chloride transport pathways, we examined the effect of the drug and of its ion transport inactive analog, NB-DGJ, in the presence of DIDS, a non-CFTR dependent inhibitor of chloride transport. Representative PD tracings obtained in F508del mice 1 hour after administration of 5 ml of 100 mM miglustat or placebo, and following addition of 200 mM DIDS diluted in chloride-free solution containing amiloride and forskolin are depicted in Figure 3A . As we have previously shown (10), alternative chloride transport pathway contributes to the largest part of the residual chloride conductance in the nasal mucosa of F508del mice. Indeed, perfusion of the nasal mucosa of placebo-treated F508del mice with DIDS reduces chloride conductance to a very low level ( Figure 3A-3B) . However, in the miglustat-treated group, PD changes after DIDS remained at least threefold higher than those values recorded in the placebo-treated group (P 5 0.005; Figure 3B ). DIDS-sensitive chloride transport was of the same magnitude in placebotreated (23.9 6 0. 5 mV) as in miglustat-treated F508del mice (24.0 6 0.4 mV; P 5 0.82). These findings indicate that the effect of miglustat in F508del-CF mice does not principally depend on alternative chloride transport pathway.
Nasal Deposition of Miglustat on Ion Transport in Cftr Knockout Mice
To determine whether the effect of miglustat on ion transport is dependent on the presence of CFTR protein, a nasal PD test was undertaken in C57Bl/6 cftr UNC knockout animals 1 hour after nasal deposition of 5 ml of 100 mM miglustat or placebo and in the corresponding wild-type mouse groups. As illustrated in Figure  4A , cftr knockout mice also demonstrated a characteristic ion transport profile consistent with increased sodium and reduced chloride conductance. After intranasal miglustat, a normalizing effect was observed on sodium but not on chloride conductance ( Figure 4A ). Indeed, mean PDmax values were significantly reduced in miglustat-treated as compared with placebo-treated cftr knockout mice ( Figure 4B ). Mean chloride conductance values remained unchanged (22.7 6 1.3 mV in placebo-treated vs. 21.8 6 0.6 mV in miglustat-treated knockout animals; P 5 0.52).
Dose-dependent Effect of Nasal Instillation of Miglustat on Ion Transport in F580del Mice
To investigate the dose-dependent effect of the intranasal deposition of miglustat in normalizing ion transport in CF, a nasal PD test was performed in F508del mice 1 hour after nasal instillation of saline or the drug applied at different doses: 5 ml in each nostril of solution of a concentration varying from 0.1 to 100 mM (i.e., a dose varying from 0.5 to 500 pmol in each nostril). After nasal deposition of 10 mM miglustat, PDmax values (218.2 6 1.0 mV; n 5 5) were similar (P 5 0.75) to those recorded after 100 mM miglustat (Figure 2A) . No effect was observed on sodium conductance following treatment with 1 mM miglustat. Indeed, mean PDmax values after 1 mM miglustat (225.4 6 1.2 mV) were similar (P 5 0.75) to the corresponding values obtained in nontreated F508del animals (223.2 6 2.1). The subthreshold dose on sodium conductance in F508del mice was confirmed for all lower doses tested (data not shown). These data indicate that the 10 mM solution corresponded to the lowest monitored dose of miglustat capable of normalizing the sodium conductance in the presence of mutant CFTR protein.
The 1 mM intranasal solution corresponded to the lowest monitored dose giving a normalizing effect on chloride conductance. As illustrated in Figure 5 , after 1 mM intranasal miglustat, SumCl voltage changes were of the same magnitude as the values recorded after deposition of 100 mM miglustat, a similar maximal normalizing effect being observed with the 10 mM solution. A subthreshold concentration on chloride transport was found to be 0.1 mM miglustat, as no significant difference was observed between chloride conductance recorded after treatment with this solution and no treatment ( Figure 5 ). An intermediate effect on chloride conductance was obtained with nasal delivery of the 0.3 mM solution ( Figure 5 ). These data indicate that a 10-fold lower concentration, compared with that able to normalize sodium conductance, is required to restore CFTR-dependent chloride transport. These data also show that 5 ml of 10 mM miglustat, corresponding to 50 pmol, is the optimal lowest intranasal dose able to normalize both sodium and chloride transepithelial transport in F508del CF mice.
Duration of the Effect of Nasal Instillation of Miglustat on Ion Transport in F580del Mice
Profiles of the nasal PD were next undertaken in F508del mice 1 hour or 6 hours after intranasal instillation of the 10 mM solution, which was selected as the optimal lowest intranasal dose. Under these conditions, no effect was observed on sodium conductance. Indeed, although it was normalized 1 hour after deposition of 10 mM miglustat, 6 hours after treatment the basal hyperpolarization in F508del animals no longer differed from that recorded in the placebo-treated group (Figure 6 ). The normalizing effect on chloride conductance, however, persisted at the same value as that recorded 1 hour after treatment ( Figure 6 ). These data indicate that the normalizing effect of picomolar intranasal dose of miglustat on chloride conductance persisted for at least 6 hours, whereas the duration of sodium transport normalization was shorter.
DISCUSSION
The present work was designed to test the hypothesis that topical delivery of miglustat into the nasal mucosa is able to overcome the ion transport defects of the mutant F508del-CFTR protein. A potential beneficial effect of miglustat in CF has been suggested through experimental studies performed in CF cell-culture lines and excised animal tissues (18) (19) (20) (21) (22) . It has been reported that 2 hours exposure of 100 mM miglustat to F508del-CFTR expressing cell-culture lines promotes an increase by 12% of the expression of mature CFTR protein to the apical cell membrane; this finding was associated with activation by 55% of the transepithelial chloride transport (18) . The finding that, in different experimental protocols (18) (19) (20) (21) (22) , miglustat has been added to polarized cell cultures grown on impermeable plastic dishes, an epithelial configuration allowing interaction of drugs through its apical side, provided the rationale for investigating the efficacy of in vivo deposition of miglustat in the airways.
A proof-of-concept phase 2a clinical trial based on oral treatment of miglustat is being conducted in patients with CF in our center. Apart from transient tremor or exacerbation of tremor reported in approximately 20% of patients on treatment with miglustat, diarrhea and weight loss are common side effects occurring in about 85 and 60% of treated patients, respectively (12) (13) (14) (15) . Whereas osmotic diarrhea appears to be the result of the disaccharidase inhibitory activity, it is unclear whether weight loss results from the diarrhea and associated gastrointestinal symptoms such as abdominal pain and flatulence, a decrease in food intake, or a combination of these or other factors. Because of the high incidence of clinically important adverse reactions (12) (13) (14) (15) , studies using CF animal models may be of relevance for evaluating the potential therapeutic efficacy of the delivery of miglustat directly to the airways before innovative development programs that target miglustat as an inhaling medication for CF can be started and before randomized, controlled trials in patients with CF can be designed. The F508del mouse model used in this work (23) shows low but detectable residual CFTR activity, nearly normal mRNA expression levels of the mutant CFTR protein, and high survival rates when compared with the two other F508del mouse models (32, 33) . Reduced chloride and increased sodium transport capacity across the respiratory epithelium are found in the F508del mouse model we use. Taken together, these properties make this model a useful in vivo system for studying novel therapeutic strategies that aim to activate chloride and reduce sodium transport function.
The preferred route of administration of any drug is one that gives direct access to its target. The choice of route is clearly influenced by the anatomical target site affected by the disease and by the physicochemical, pharmacological, and toxicological properties of the drug or vehicle used. Topical administration of drugs along the airway tree through the inhalation of a nebulized liquid or dry powder formulation has been used extensively in the treatment of CF and other pulmonary diseases. The large airway surface area and its decreased metabolic capacity relative to the gastrointestinal tract offer an attractive portal for airway delivery of drugs. The physiochemical properties of miglustat as a low molecular weight and a highly water-soluble molecule eliminating the need to use potentially toxic solvents would represent additional advantages. Small aerodynamic size particles formed, for instance, by nebulization of an aqueous solution could efficiently deliver miglustat to the lower lungs for a local effect (34) . Deposition of miglustat in the airways would advantageously minimize systemic undesirable effects and the amount of drug required to locally achieve therapeutic levels.
In the present work, we showed that in vivo deposition of a picomolar dose of miglustat applied directly to the respiratory epithelium efficiently corrects ion transport abnormalities of the F508del-CFTR protein. The response was characterized by an early and complete correction of both sodium and chloride conductances. When administered orally (20) , correcting effects of miglustat on the F508del mouse nasal mucosa required a dose approximately 120-fold larger than the human therapeutic dose used in Gaucher disease (1,200 mg/kg/d to mice vs. z10 mg/kg/d or 200 mg three times a day to adult patients). The duration of the normalizing effect on chloride conductance could be related to the effective half-life of miglustat, reported to be 6.3 hours in humans (12) . This is in keeping with a report that the correcting effect of the miglustat to CF cells in culture is time dependent; the effect of a final concentration of 100 mM progressively declined after 4 to 6 hours with a total loss of effect after 14 hours (22) .
The precise mechanism of action of miglustat for correcting chloride and sodium transport of F508del-CFTR protein is not clear. Our data showed that chloride transport after perfusion with DIDS, a commonly used inhibitor of alternative chloride channels (35) and electrogenic anion exchangers (36) in murine epithelia, was much higher in F508del mice in the presence of miglustat when compared with the galactose iminosugar derivative. This observation, in addition to the finding that the effect on chloride conductance was lost in cftr knockout mice, supports the notion that the normalizing effect of miglustat on chloride transport involves F508del-CFTR and not an alternative chloride transport pathway. It has been shown that miglustat prevents the interaction of F508del-CFTR protein to the chaperone calnexin (18) , an ER-localized lectin-like protein involved in the CFTR biogenesis. Effectively, calnexin binds N-linked glycans, and two such glycosylation sites have been identified on CFTR in the extracellular loop four of the membrane spanning domain (MSD)-2 (37). Knockdown of calnexin leads a large portion of nascent CFTR to misfold (37, 38 ). Yet, the mechanism for calnexin action in folding and quality control of CFTR is not well understood, and studies on the role of calnexin in degradation and rescue of misfolded F508del-CFTR protein have provided mixed results. Although the overexpression of calnexin seems to favor accumulation of F508del-CFTR in the ER (38) , siRNA-mediated down-regulation of calnexin does not inhibit degradation of wild-type or mutant F508del-CFTR (37, 38) . Investigation has shown that binding to calnexin is not essential for degradation of wild-type or misfolded F508del-CFTR. Folding defects of the mutant protein have been evidenced either before or after the calnexin-dependent association of MSD-1 and MSD-2 (39) . Therefore, the inhibition of ER a-1,2-glucosylation of nascent CFTR protein by miglustat is probably not sufficient to completely restore the localization and the functional rescue of the misfolded protein as suggested (18) . It could be possible that miglustat interferes with the efficiency level of the quality control of CFTR maturation and that normalizing drug effects could be associated with a less efficient quality-control system as observed in our F508del-CF mouse model that shows low but detectable residual CFTR function.
Our data are in agreement with those from Noel and colleagues (20) in which sodium conductance in CF airway epithelial cultured cells and excised nasal mucosa from F508del mice were normalized after miglustat treatment. Data from this group (20) have shown that the magnitude of the amiloride-sensitive current is similar in the presence or the absence of forkolin/genistein, intended to open CFTR channels, arguing that activation of F508del-CFTR is not required for the down-regulating effect of miglustat on sodium conductance. However, as no significant effect on amiloride-sensitive current could be observed in nasal mucosa excised from orally treated cftr knockout mice (20) , the authors concluded that the effect of miglustat is due to F508del-cftr rescue. In contrast, data from our work indicate that the corrective effect of miglustat on sodium conductance does not seem to be dependent on the functional rescue of CFTR. Indeed, a normalizing effect of intranasal deposition of up to 10 mM miglustat solution on sodium conductance was clearly evidenced in the absence of cftr protein. Moreover, in the presence of the mutant protein, the duration of the effect was shorter, and a 10-fold higher effective dose was required for normalizing sodium conductance compared with the dose able to restore chloride conductance. A highly variable dataset with large dispersion around the mean (20) might, at least partly, explain differences between the work from Noel and colleagues (20) and ours. Likewise, the choice of the route of administration and the distinct dose potencies required for normalizing chloride and sodium conductances could additionally contribute to the differences found. As the positive effect of miglustat on chloride secretion remained evident in the absence of normalization of sodium transport, it does not support a counteracting effect of ENaC on CFTR. This is in keeping with studies performed in the bENaC overexpressing mouse model (40) that develops a severe CF-like lung disease with airway liquid depletion, mucus retention, neutrophilic infiltration, but not the other aspects of CFTR dysfunction (41) . Further preclinical pharmacokinetic and NPD in vivo studies assessing different doses and routes of administration, including airway delivery, to be conducted in the bENaC mouse model (40) , would help confirm the finding that miglustat acts on sodium conductance through a direct effect on ENaC activity.
Another interesting observation of the effect of miglustat in CF is that, apart from its normalizing effect on ion transport, the drug has an antiinflammatory action (21) . Actually, it has been reported that exposure for 24 hours to 200 mM of miglustat (but also to its ion transport inactive analog NB-DGJ) reduced the expression of proinflammatory mediators induced by Pseudomonas aeruginosa infection, tumor necrosis factor (TNF)-a, or IL-1b in bronchial epithelial cells in culture. Considering that airway inflammation is a hallmark of CF lung disease, further confirmation of the antiinflammatory effect of miglustat on topical delivery of picomolar doses to the airway tree could be largely beneficial for CF airway disease.
Besides reducing cellular levels of glycosphingolipids, miglustat, as an inhibitor of glucosylceramide-based glycosphingolipids, conversely induces ceramide accumulation (27) . Recent studies have shown that both patients with CF and cftr knockout mice display lower levels of ceramide in plasma, lungs, and other CFaffected organs (42) . The regulation of ceramide levels seems to be crucial for the maintenance of proper membrane permeabilization properties and homeostasis of inflammatory responses. It could therefore be postulated that, as evidenced for fenretinide, a semisynthetic retinoid (42) , beneficial effects of miglustat might, at least partly, be mediated by correction of the ceramide defect.
We demonstrate that local delivery of a single picomolar dose of miglustat, an approved drug for oral treatment of Gaucher disease, to the airways of F508del-CF mice corrects both reduced chloride and exaggerated sodium transport. The effect is apparently dependent on CFTR-mediated chloride transport. Our data provide a strong rationale for airway delivery of miglustat for patients with CF lung disease.
